Vertex Pharmaceuticals has entered a strategic collaboration with Ribometrix to discover potential RNA-targeted therapies for serious diseases. Vertex is a leader in…
Articles by Ana Pena, PhD
Scientists have created a miniature human pancreas-on-a-chip that may help identify the cause of cystic fibrosis-related diabetes (CFRD), a common…
AR-501, an investigational inhaled formulation of gallium citrate to treat chronic lung infections in patients with cystic…
Armata Pharmaceuticals‘ investigational phage therapy AP-PA01 combined with antibiotics holds promise for treating multidrug-resistant Pseudomonas airway infections, updated data…
Vertex Pharmaceuticals selected its VX-445 (elexacaftor) triple regimen to apply…
A pharmaceutical sciences researcher will use a five-year, $3.3 million grant from the National Institutes of Health (NIH) to develop…
Having to take insulin to treat cystic fibrosis-related diabetes (CFRD)Â adds to…
A simple new test may help identify which CFTR modulators are more effective…
Using antibiotics to fully eliminate new methicillin-resistant Staphylococcus aureus (MRSA)…
Bacteria species of the genus Streptococcus and Haemophilus are the most common in airways of children with cystic fibrosis (CF) for their…